Toxicology in the critically ill patient

Clinics in Chest Medicine

Volumn 24, Issue 4, 2003, Pages 689-711

  Mokhlesi, Babak ^a   Corbridge, Thomas ^b  

^a Jr Hospital of Cook County   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ATROPINE; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMATE INSECTICIDE; COCAINE; DEXTROMETHORPHAN; EPHEDRINE; FLUMAZENIL; ILLICIT DRUG; LYSERGIDE; NALOXONE; NEUROLEPTIC AGENT; OPIATE AGONIST; PHENOTHIAZINE DERIVATIVE; PHYSOSTIGMINE; PILOCARPINE; PRALIDOXIME; PROPANTHELINE BROMIDE; SALBUTAMOL; SCOPOLAMINE; TERBUTALINE; THEOPHYLLINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACCIDENT; ANTICHOLINERGIC EFFECT; BIOLOGICAL WARFARE; CHEMICAL WARFARE; CLINICAL FEATURE; CRITICAL ILLNESS; DRUG OVERDOSE; EARLY DIAGNOSIS; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HUMAN; INTOXICATION; PRIORITY JOURNAL; REVIEW; SUICIDAL BEHAVIOR;

EID: 0347624022     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00097-2     Document Type: Review

References (209)

1. Litovitz TL, Klein-Schwartz W, White S, et al. 2000 Annual Report of the American Association of Poison Control Centers toxic exposure surveillance system. Am J Emer Med 2001;19(5):337-95.
2. Wright N. An assessment of the unreliability of the history given by self-poisoned patients. Clin Toxicol 1980;16:381-4.
3. Olson KR, Pentel PR, Kelley MT. Physical assessment and differential diagnosis of the poisoned patient. Med Toxicol 1987;2(1):52-81.
4. Mokhlesi B, Leikin JB, Murray P, et al. Adult toxicology in critical care: part I: general approach to the intoxicated patient. Chest 2003;123(2):577-92.
5. Sweeney TE, Beuchat CA. Limitations of methods of osmometry: measuring the osmolality of biological fluids. Am J Physiol 1993;264:R469-80.
6. Walker JA, Schwartzbard A, Krauss EA, et al. The missing gap: a pitfall in the diagnosis of alcohol intoxication by osmometry. Arch Intern Med 1986;146:1843-4.
7. Glasser L, Sternglanz PD, Combie J, et al. Serum osmolality and its applicability to drug overdose. Am J Clin Path 1973;60:695-9.
8. Hoffman RS, Smilkstein MJ, Howland MA, et al. Osmolal gaps revisited: normal values and limitations. J Toxicol Clin Toxicol 1993;31:81-93.
9. Tremper KK, Barker SJ. Pulse oximetry. Anesthesiology 1989;70:98-108.
10. Barker SJ, Tremper KK, Hyatt J. Effects of methemoglobinemia on pulse oximetry and mixed venous oximetry. Anesthesiology 1989;70:112-7.
11. LeGrand TS, Peters JI. Pulse oximetry: advantages and pitfalls. J Crit Illness 1999;20:195-206.
12. Hampson NB. Pulse oximetry in severe carbon monoxide poisoning. Chest 1998;114(4):1036-41.
13. Bozeman WP, Myers RA, Barish RA. Confirmation of the pulse oximetry gap in carbon monoxide poisoning. Ann Emerg Med 1997;30:608-11.
14. Brett AS. Implications of discordance between clinical impression and toxicology analysis in drug overdose. Arch Intern Med 1988;148:437-41.
15. Kellerman AL, Fihn SD, LoGerfo JP, et al. Impact of drug screening in suspected overdose. Ann Emerg Med 1987;16:1209-16.
16. Mahoney JD, Gross PL, Stern TA, et al. Quantitative serum toxic screening in the management of suspected drug overdose. Am J Emer Med 1990;8:16-22.
17. Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness: controversies in the use of a "coma cocktail". JAMA 1995;274:562-9.
18. Weinbroum A, Rudick V, Sorkine P, et al. Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients. Crit Care Med 1996;24:199-206.
19. Krenzelok EP, McGuigan M, Lheur P. Position statement: ipecac syrup. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997;35:699-709.
20. Vale JA, Meredith TJ, Proudfoot AT. Syrup of ipecacuanha: is it really useful? BMJ 1986;293:1321-2.
21. Vale JA. American Academy of Clinical Toxicology, European Association of Poison Centres and Clinical Toxicologists. Position statement: gastric lavage. J Toxicol Clin Toxicol 1997;35:711-9.
22. Barceloux D, McGuigan M, Hartigan-Go K. Position statement: cathartics. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997;35:743-52.
23. Tenenbein M. American Academy of Clinical Toxicology, European Association of Poison Centres and Clinical Toxicologists. Position statement: whole bowel irrigation. J Toxicol Clin Toxicol 1997;35:753-62.
24. Vale JA, Krenzelok EP, Barceloux GD, et al. Position statement and practice guidelines on the use of multidose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999;37(6): 731-51.
25. Brett AS, Rothschild N, Gray R, et al. Predicting the clinical course in intentional drug overdose: implications for the use of the intensive care unit. Arch Intern Med 1987;147:133-7.
26. Hamad AE, Al-Ghadban A, Carvounis CP, et al. Predicting the need for medical intensive care monitoring in drug-overdosed patients. J Intensive Care Med 2000;15(6):321-8.
27. Kulling P, Persson H. The role of the intensive care unit in the management of the poisoned patient. Med Toxicol 1986;1:375-86.
28. Rumack BH. Acetaminophen poisoning. Am J Med 1983;75:104-12.
29. Rumack BH. Acetaminophen overdose in children and adolescents. Pediatr Clin N Am 1986;33:691-701.
30. Rumack BH, Matthew M. Acetaminophen poisoning and toxicity. Pediatrics 1975;55:871-6.
31. Bizovi K, Keys N, Rivas J, et al. Tylenol ER, late rise of APAP level after overdose. J Toxicol Clin Toxicol 1995;33:510.
32. Douglas DR, Sholar JB, Smilkstein MJ. A pharmacokinetic comparison of acetaminophen products (tylenol extended relief vs. regular tylenol). Acad Emer Med 1996;3:740-4.
33. Stork CM, Rees S, Howland MA, et al. Pharmacokinetics of extended relief vs. regular release tylenol in a simulated human overdose. J Toxicol Clin Toxicol 1996;34:157-62.
34. Whitcomb DC, Block GD. Association of acetaminophen with fasting and ethanol abuse. JAMA 1994;272:1845-50.
35. Schiodt FV, Rochling FA, Casey DL, et al. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997;16:1112-7.
36. Bond GR, Lite LK. Population-based incidence and outcome of acetaminophen poisoning by type of ingestion. Acad Emerg Med 1999;6:1115-20.
37. Spiller HA, Krenzelok EP, Grande GA, et al. A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose. Ann Emerg Med 1994;23:519-23.
38. Brent J. Are activated charcoal-N-acetylcysteine interactions of clinical significance? Ann Emerg Med 1993;22:1860-1.
39. Buckley NA, Whyte IM, O'Connell DL, et al. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999;37:753-7.
40. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976-1985). N Engl J Med 1988;319:1557-62.
41. Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990;335:1572-3.
42. Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991;324:1852-7.
43. Buckley NA, Whyte IM, O'Connell DL, et al. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? J Toxicol Clin Toxicol 1999;37:759-67.
44. Amirzadeh A, McCotter C. The intravenous use of oral acetylcysteine (mucomyst) for the treatment of acetaminophen overdose. Arch Intern Med 2002;162:96-7.
45. Yip L, Dart RC, Hurlbut KM. Intravenous administration of oral N-acetylcysteine. Crit Care Med 1998;26:40-3.
46. Bailey B, McGuigan MA. Management ofanaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med 1998;31:710-5.
47. Woo OF, Mueller PD, Olson KR, et al. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann Emerg Med 2000;35:363-8.
48. Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. BMJ 1979;2:1097-100.
49. Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991;20:1058-63.
50. Ostapowicz G, Lee WM. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol 2000;15:480-8.
51. Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999;5:29-34.
52. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
53. Mitchell I, Bihari D, Chang R, et al. Earlier identification of patients at risk from acetaminophen-induced acute liver failure. Crit Care Med 1998;26:279-84.
54. Gabow PA. Ethylene glycol intoxication. Am J Kid Dis 1988;11:277-9.
55. Wine H, Savitt D, Abuelo JG. Ethylene glycol intoxication. Semin Dial 1994;7:338-45.
56. Krenzelok EP, Leikin JB. Approach to a poisoned patient. Dis Mon 1996;42:509-608.
57. Palmer BF, Eigenbrodt EH, Henrich WL. Cranial nerve deficit: a clue to the diagnosis of ethylene glycol poisoning. Am J Med 1989;87:91-2.
58. Mallya KB, Mendis T, Guberman A. Bilateral facial paralysis following ethylene glycol toxicity. Can J Neurol Sci 1986;13:340-1.
59. Kruse JA. Methanol poisoning. Intensive Care Med 1992;18:391-7.
60. Hantson P, Mahieu P. Pancreatic injury following acute methanol poisoning. J Toxicol Clin Toxicol 2000;38:297-303.
61. Brent J. Current management of ethylene glycol poisoning. Drugs 2001;61:979-88.
62. Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. N Engl J Med 1999;340:832-8.
63. Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of methanol poisoning. N Engl J Med 2001;344:424-9.
64. Mycyk MB, Leikin JB. Antidote review: fomepizole for methanol poisoning. Am J Ther 2003;10:68-70.
65. Pappas AA, Ackerman BH, Olsen KM, et al. Isopropanol ingestion: a report of six episodes with isopropanol and acetone serum concentration time data. J Toxicol Clin Toxicol 1991;29:11-21.
66. Lacouture PG, Wason S, Abrams A, et al. Acute isopropyl alcohol intoxication: diagnosis and management. Am J Med 1983;75:680-6.
67. Richards JR, Bretz SW, Johnson EB, et al. Methamphetamine abuse and emergency department utilization. West J Med 1999;170:198-202.
68. Substance Abuse and Mental Health Services Administration (SAMHSA) Drug Abuse Warning Network (DAWN): Club Drugs, 2001 update. Available at: http://www.samhsa.gov/oas/2k2/DAWN/clubdrugs 2kl.pdf. Accessed February 16, 2003.
69. Lan KC, Lin YF, Yu FC, et al. Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc 1998;97:528-33.
70. Richards JR, Johnson EB, Stark RW, et al. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med 1999;17:681-5.
71. Jones AL, Simpson KJ. Mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 1999;12:129-33.
72. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992;340:384-7.
73. Byard RW, Gilbert J, James R, et al. Amphetamine derivative fatalities in South Australia - is "ecstasy" the culprit? Am J Forensic Med Pathol 1998;19:261-5.
74. Richards JR, Derlet RW, Duncan DR. Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med 1997;4:130-5.
75. Jones AL, Volans G. Management of self poisoning. BMJ 1999;319:1414-7.
76. Denborough MA, Hopkinson KC. Dantrolene and "ecstasy". Med J Aust 1997;166:165-6.
77. Watson JD, Ferguson C, Hinds CJ, et al. Exertional heat stroke caused by amphetamine analogues. Does dantrolene have a place? Anaesthesia 1993;48:1057-60.
78. Cobb N, Etzel RA. Unintentional carbon monoxide related deaths in the United States. JAMA 1991;266:659-63.
79. Hart IK, Kennedy PGE, Adams JH, et al. Neurological manifestation of carbon monoxide poisoning. Postgrad Med J 1988;64:213-6.
80. Sawa GM, Watson CPM, Terbrugge K, et al. Delayed encephalopathy following carbon monoxide intoxication. Can J Neurol Sci 1981;8:77-9.
81. Choi IS. Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol 1983;40:433-5.
82. Touger M, Gallagher EJ, Tyrell J. Relationship between venous and arterial carboxyhemoglobin levels in patients with suspected carbon monoxide poisoning. Ann Emerg Med 1995;25:481-3.
83. Buckley RG, Aks SE, Eshom JL, et al. The pulse oximetry gap in carbon monoxide intoxication. Ann Emerg Med 1994;24:252-5.
84. Hampson NB. Pulse oximetry in severe carbon monoxide poisoning. Chest 1998;114:1036-41.
85. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996;334:1642-8.
86. Juurlink DN, Stanbrook MB, McGuigan MA. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2000;2:CD002041.
87. Weaver LK, Hopkins RO, Chan KJ, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med 2002;347(14):1057-67.
88. Thom SR, Taber RL, Mendiguren II, et al. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med 1995;25:474-80.
89. Daras M, Tuchman AJ, Koppel BS, et al. Neurovascular complications of cocaine. Acta Neurol Scand 1994;90:124-9.
90. Lange RA, Hillis LD. Medical progress: cardiovascular complications of cocaine use. N Engl J Med 2001;345:351-8.
91. Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Cocaine Associated Chest Pain (COCHPA) Study Group. Acad Emerg Med 1994;1:330-9.
92. Weber JE, Shofer FS, Larkin GL, et al. Validation of a brief observation period for patients with cocaine-associated chest pain. N Engl J Med 2003;348(6): 510-7.
93. Albertson TE, Walby WF, Derlet RW. Stimulant-induced pulmonary toxicity. Chest 1995;108:1140-9.
94. Roth D, Alarcon FJ, Fernandez JA, et al. Acute rhabdomyolysis associated with cocaine intoxication. N Engl J Med 1988;319:673-7.
95. Brogan WC, Lange RA, Kim AS, et al. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. J Am Coll Card 1991;18:581-6.
96. Sand IC, Brody SL, Wrenn KD, et al. Experience with esmolol for the treatment ofcocaine-associated cardiovascular complications. Am J Emerg Med 1991;9:161-3.
97. Boehrer JD, Moliterno DJ, Willard JE, et al. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 1993;94:608-10.
98. Sofuoglu M, Brown S, Babb DA, et al. Effects of labetalol treatment on the physiological and subjective response to smoked cocaine. Pharmacol Biochem Behav 2000;65:255-9.
99. Hollander JE, Carter WA, Hoffman RS. Use of phentolamine for cocaine-induced myocardial ischemia. N Engl J Med 1992;327:361.
100. Forrester JM, Steele AW, Waldron JA, et al. Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histopathologic findings. Am Rev Respir Dis 1990;142:462-7.
101. Blanc PD. Cyanide. In: Olson KR, editor. Poisonings and drug overdose. 3rd edition. Stamford (CT): Appleton and Lange; 1999. p. 150-2.
102. Yeh MM, Becker CE, Arieff AI. Is measurement of venous oxygen saturation useful in the diagnosis of cyanide poisoning? Am J Med 1992;93:582-3.
103. Litovitz TL, Larkin RF, Myers RA. Cyanide poisoning treated with hyperbaric oxygen. Am J Emerg Med 1983;1:94-101.
104. Kirk MA, Gerace R, Kulig KW. Cyanide and methemoglobin kinetics in smoke inhalation victims treated with the cyanide antidote kit. Ann Emerg Med 1993;22:1413-8.
105. Robin ED, McCauley R. Nitroprusside-related cyanide poisoning. Time (long past due) for urgent, effective interventions. Chest 1992;102:1842-5.
106. Forsyth JC, Mueller PD, Becker CE, et al. Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. J Toxicol Clin Toxicol 1993;31:277-94.
107. Sauer SW, Keim ME. Hydroxocobalamin: improved public health readiness for cyanide disasters. Ann Emerg Med 2001;37:635-41.
108. Houeto P, Borron SW, Sandouk P, et al. Pharmacokinetics of hydroxocobalamin in smoke inhalation victims. J Toxicol Clin Toxicol 1996;34(4):397-404.
109. Houeto P, Hoffman JR, Imbert M, et al. Relation of blood cyanide to plasma cyanocobalamin concentration after a fixed dose of hydroxocobalamin in cyanide poisoning. Lancet 1995;346:605-8.
110. Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985;313:474-9.
111. Buckley NA, O'Connell DL, Whyte IM, et al. Interrater agreement in the measurement of QRS interval in tricyclic antidepressant overdose: implications for monitoring and research. Ann Emerg Med 1996;28:515-9.
112. Harrigan RA, Brady WJ. ECG abnormalities in tricyclic antidepressant ingestion. Am J Emerg Med 1999;17:387-93.
113. Stern TA, O'Gara PT, Mulley AG, et al. Complications after overdose with tricyclic antidepressants. Crit Care Med 1985;13:672-4.
114. Bosse GM, Barefoot JA, Pfeifer MP, et al. Comparison of three methods of gut decontamination in tricyclic antidepressant overdose. J Emerg Med 1995;13:203-9.
115. Vale JA, Krenzelok EP, Barceloux GD, et al. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999;37:731-51.
116. Mayron R, Ruiz E. Phenytoin: does it reverse tricyclic-antidepressant-induced cardiac conduction abnormalities? Ann Emerg Med 1986;15:876-80.
117. Callaham M, Schumaker H, Pentel P. Phenytoin prophylaxis of cardiotoxicity in experimental amitriptyline poisoning. J Pharmacol Exp Ther 1988;245:216-20.
118. Merigian KS, Hedges JR, Kaplan LA, et al. Plasma catecholamine levels in cyclic antidepressant overdose. J Toxicol Clin Toxicol 1991;29:177-90.
119. Buchman AL, Dauer J, Geiderman J, et al. The use of vasoactive agents in the treatment of refractory hypotension seen in tricyclic antidepressant overdose. J Clin Psychopharmacol 1990;10:409-13.
120. Teba L, Schiebel F, Dedhia HV, et al. Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose. Am J Emerg Med 1988;6:566-8.
121. Zuckerman GB, Conway EE. Pulmonary complications following tricyclic antidepressant overdose in an adolescent. Ann Pharmacother 1993;27:572-4.
122. Shannon M, Lovejoy FH. Pulmonary consequences of severe tricyclic antidepressant ingestion. J Toxicol Clin Toxicol 1987;25:443-61.
123. Taboulet P, Michard F, Muszynski J, et al. Cardiovascular repercussions of seizures during cyclic antidepressant poisoning. J Toxicol Clin Toxicol 1995;33:205-11.
124. Merigian KS, Browning RG, Leeper KV. Successful treatment of amoxapine-induced refractory status epilepticus with propofol (diprivan). Acad Emerg Med 1995;2:128-33.
125. Callaham M, Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emerg Med 1985;14:1-9.
126. Callaham M. Admission criteria for tricyclic antidepressant ingestion. West J Med 1982;137:425-9.
127. Tokarski GF, Young MJ. Criteria for admitting patients with tricyclic antidepressant overdose. J Emerg Med 1988;6:121-4.
128. Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB) - a neuroactive drug with abuse potential. Toxicol Clin Toxicol 1997;35:581-90.
129. Chin RL, Sporer KA, Cullison B, et al. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998;31:716-22.
130. Davis LG. Fatalities attributed to GHB and related compounds. South Med J 1999;92:1037.
131. Yates SW, Viera AJ. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose. Mayo Clin Proc 2000;75:401-2.
132. Mullins ME, Dribben W. Physostigmine treatment of gamma-hydroxybutyric acid overdose: appropriate or inappropriate use of a reversal agent? Mayo Clin Proc 2000;75:872-3.
133. ElSohly MA, Salamone SJ. Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol 1999;23:141-6.
134. LeBeau MA, Montgomery MA, Miller ML, et al. Analysis of biofluids for gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) by headspace GC-FID and GC-MS. J Anal Toxicol 2000;24:421-8.
135. Kalasinsky KS, Dixon MM, Schmunk GA, et al. Blood, brain, and hair GHB concentrations following fatal ingestion. J Forensic Sci 2001;46(3):728-30.
136. Sinex JE. Pulse oximetry: principles and limitations. Am J Emerg Med 1999;17:59-67.
137. Donnelly GB, Randlett D. Images in clinical medicine. Methemoglobinemia. New Engl J Med 2000;343:337.
138. Corbridge TC, Murray P. Toxicology in adults. In: Hall J, Schmidt GS, Wood LDH, editors. Principles of critical care. New York: McGraw Hill; 1998. p. 1473-525.
139. Sternbach G. William Osler: narcotic-induced pulmonary edema. J Emerg Med 1983;1:165-7.
140. Katz S, Abennan A, Frand UI, et al. Heroin pulmonary edema. Evidence for increased pulmonary capillary permeability. Am Rev Respir Dis 1972;106:472-4.
141. Sporer KA, Dorn E. Heroin-related noncardiogenic pulmonary edema: a case series. Chest 2001;120:1628-32.
142. Corbridge T, Cygan J, Greenberger P. Substance abuse and acute asthma. Intensive Care Med 2000;26:347-9.
143. Cygan J, Trunsky M, Corbridge T. Inhaled heroin-induced status asthmaticus: five cases and a review of the literature. Chest 2000;117:272-5.
144. Krantz AJ, Hershow RC, Prachand N, et al. Heroin insufflation as a trigger for patients with life-threatening asthma. Chest 2003;123(2):510-7.
145. Marinella MA. Meperidine-induced generalized seizures with normal renal function. South Med J 1997;90:556-8.
146. Hershey LA. Meperidine and central neurotoxicity. Ann Intern Med 1983;98:548-9.
147. Sporer KA. Acute heroin overdose. Ann Intern Med 1999;130:584-90.
148. Darke S, Zador D. Fatal heroin 'overdose': a review. Addiction 1996;91:1765-72.
149. Zador D, Sunjic S, Darke S. Heroin-related deaths in New South Wales, 1992: toxicological findings and circumstances. Med J Aust 1996;164:204-7.
150. Ruttenber AJ, Kalter HD, Santinga P. The role of ethanol abuse in the etiology of heroin-related death. J Forensic Sci 1990;35:891-900.
151. Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med 1991;20:246-52.
152. Goldfrank LR, Hoffman RS. The poisoned patient with altered consciousness. JAMA 1995;274:562-9.
153. Tandberg D, Abercrombie D. Treatment of heroin overdose with endotracheal naloxone. Ann Emerg Med 1982;11:443-5.
154. Goldfrank LR. The several uses of naloxone. Emerg Med 1984;16(10):105-16.
155. Geller RJ, Singleton KL, Tarantino ML, et al. Nosocomial poisoning associated with emergency department treatment of organophosphate toxicity-Georgia, 2000. J Toxicol Clin Toxicol 2001;39:109-11.
156. Vale JA. Toxicokinetic and toxicodynamic aspects of organophosphorus (OP) insecticide poisoning. Toxicol Lett 1998;102:649-52.
157. Sungur M, Guven M. Intensive care management of organophosphate insecticide poisoning. Crit Care (London) 2001;5:211-5.
158. Namba T, Nolte CT, Jackrel J, et al. Poisoning due to organophosphate insecticides. Acute and chronic manifestations. Am J Med 1971;50:475-92.
159. Hayes MM, van der Westhuizen NG, Gelfand M. Organophosphate poisoning in Rhodesia. A study of the clinical features and management of 105 patients. S Afr Med J 1978;54:230-4.
160. Saadeh AM, Farsakh NA, al-Ali MK. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart 1997;77:461-4.
161. Coye MJ, Barnett PG, Midtling JE, et al. Clinical confirmation of organophosphate poisoning by serial cholinesterase analyses. Arch Intern Med 1987;147:438-42.
162. Nouira S, Abroug F, Elatrous S, et al. Prognostic value of serum cholinesterase in organophosphate poisoning. Chest 1994;106:1811-4.
163. Bardin PG, Van Eeden SF. Organophosphate poisoning: grading the severity and comparing treatment between atropine and glycopyrrolate. Crit Care Med 1990;18:956-60.
164. Lee P, Tai DY. Clinical features of patients with acute organophosphate poisoning requiring intensive care. Intensive Care Med 2001;27:694-9.
165. Goswamy R, Chaudhuri A, Mahashur AA. Study of respiratory failure in organophosphate and carbamate poisoning. Heart Lung 1994;23:466-72.
166. Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med 1981;141:364-9.
167. Eichenholz A, Mulhausen RO, Redleaf PS. Nature of acid-base disturbance in salicylate intoxication. Metabolism 1963;12:164-75.
168. Gabow PA, Anderson RJ, Potts DE, et al. Acid-base disturbances in the salicylate-intoxicated adult. Arch Intern Med 1978;138:1481-4.
169. Hill JB. Salicylate intoxication. N Engl J Med 1973;288:1110-3.
170. Thisted B, Kantz T, Strom J, et al. Acute salicylate self-poisoning in 177 patients treated in ICU. Acta Anaesth Scand 1987;31:312-6.
171. Done AK. Salicylate intoxication. Pediatrics 1960;26:800-7.
172. Dugandzic RM, Tierny MG, Dickinson GE, et al. Evaluation of the validity of the Done nomogram in the management of acute salicylate intoxication. Ann Emerg Med 1989;18:1186-90.
173. Pierce RP, Gazewood J, Blake RL. Salicylate poisoning from enteric-coated aspirin. Delayed absorption may complicate management. Postgrad Med 1991;89:61-4.
174. Anderson RJ, Potts DE, Gabow PA, et al. Unrecognized adult salicylate intoxication. Ann Intern Med 1976;85:745-8.
175. Greer HD, Ward HP, Corbin KB. Chronic salicylate intoxication in adults. JAMA 1965;193:85-8.
176. Heffner JE, Sahn SA. Salicylate-induced pulmonary edema. Ann Intern Med 1981;95:405-9.
177. Prescott LF, Balali-Mood M, Critchley JA, et al. Diuresis or urinary alkalinisation for salicylate poisoning? BMJ 1982;285:1383-6.
178. Garella S. Extracorporeal techniques in the treatment of exogenous intoxications. Kidney Int 1988;33:735-54.
179. Greenfield RA, Brown BR, Hutchins JB, et al. Microbiological, biological, and chemical weapons of warfare and terrorism. Am J Med Sci 2002;323(6): 326-40.
180. Greenfield RA, Drevets DA, Machado LJ, et al. Bacterial pathogens as biological weapons and agents of bioterrorism. Am J Med Sci 2002;323(6):299-315.
181. Bronze MS, Huycke MM, Machado LJ, et al. Viral agents as biological weapons and agents of bioterrorism. Am J Med Sci 2002;323(6):316-25.
182. Greenfield RA, Lutz BD, Huycke MM, et al. Unconventional biological threats and the molecular biological response to biological threats. Am J Med Sci 2002;323(6):350-7.
183. Hogan DE, Kellison T. Nuclear terrorism. Am J Med Sci 2002;323(6):341-9.
184. Gunderson CH, Lehmann CR, Sidell FR, et al. Nerve agents: a review. Neurology 1992;42(5):946-50.
185. Evison D, Hinsley D, Rice P. Chemical weapons. BMJ 2002;324(7333):332-5.
186. Leikin JB, Thomas RG, Walter FG, et al. A review of nerve agent exposure for the critical care physician. Crit Care Med 2002;30(10):2346-54.
187. Holstege CP, Kirk M, Sidell FR. Chemical warfare. Nerve agent poisoning. Crit Care Clin 1997;13(4): 923-42.
188. Nozaki H, Aikawa N, Shinozawa Y, et al. Sarin poisoning in Tokyo subway. Lancet 1995;345(8955):980-1.
189. Nozaki H, Hori S, Shinozawa Y, et al. Secondary exposure of medical staff to sarin vapor in the emergency room. Intensive Care Med 1995;21(12):1032-5.
190. Farmer JC, Carlton Jr PK. Who is 9-1-1 to the 9-1-1? Crit Care Med 2002;30(10):2397-8.
191. Sohrabpour H. Clinical manifestations of chemical agents on Iranian combatants during Iran-Iraq conflict. Arch Belg 1984;(Suppl)291-7.
192. Dacre JC, Goldman M. Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Pharmacol Rev 1996;48(2):289-326.
193. Wormser U. Toxicology of mustard gas. Trends Pharmacol Sci 1991;12(4):164-7.
194. Borak J, Sidell FR. Agents of chemical warfare: sulfur mustard. Ann Emerg Med 1992;21(3):303-8.
195. Borak J, Diller WF. Phosgene exposure: mechanisms of injury and treatment strategies. J Occup Environ Med 2001;43(2):110-9.
196. Sciuto AM, Strickland PT, Kennedy TP, et al. Postexposure treatment with aminophylline protects against phosgene-induced acute lung injury. Exp Lung Res 1997;23(4):317-32.
197. Sciuto AM, Strickland PT, Kennedy TP, et al. Protective effects of N-acetylcysteine treatment after phosgene exposure in rabbits. Am J Respir Crit Care Med 1995;151(3 Pt 1):768-72.
198. Olsnes S, Kozlov JV. Ricin. Toxicon 2001;39(11): 1723-8.
199. Rosenbloom M, Leikin JB, Vogel SN, et al. Biological and chemical agents: a brief synopsis. Am J Ther 2002;9(1):5-14.
200. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287(17): 2236-52.
201. Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J Med 1999;341(11):815-26.
202. Swartz MN. Recognition and management of anthrax - an update. N Engl J Med 2001;345(22):1621-6.
203. Bush LM, Abrams BH, Beall A, et al. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med 2001;345(22):1607-10.
204. Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346(17): 1300-8.
205. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999;281(22):2127-37.
206. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285(8):1059-70.
207. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000;283(17):2281-90.
208. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287(18): 2391-405.
209. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285(21):2763-73.